AR081315A1 - Derivados heterociclicos de piperidin y pirimidin -4-il-azetidina, una forma cristalina de la sal del acido acetonitriladipico de un derivado pirimidinico, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades relacionadas con la inhibicion de jak-1, t - Google Patents
Derivados heterociclicos de piperidin y pirimidin -4-il-azetidina, una forma cristalina de la sal del acido acetonitriladipico de un derivado pirimidinico, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades relacionadas con la inhibicion de jak-1, tInfo
- Publication number
- AR081315A1 AR081315A1 ARP110100737A ARP110100737A AR081315A1 AR 081315 A1 AR081315 A1 AR 081315A1 AR P110100737 A ARP110100737 A AR P110100737A AR P110100737 A ARP110100737 A AR P110100737A AR 081315 A1 AR081315 A1 AR 081315A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- heterocycloalkyl
- heteroaryl
- aryl
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 238000002347 injection Methods 0.000 title 1
- 239000007924 injection Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 24
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 14
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 12
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 12
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 12
- 125000001072 heteroaryl group Chemical group 0.000 abstract 12
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 12
- 125000000217 alkyl group Chemical group 0.000 abstract 11
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 10
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 8
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 8
- 125000001475 halogen functional group Chemical group 0.000 abstract 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 5
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 5
- 229910052799 carbon Inorganic materials 0.000 abstract 5
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 4
- 125000005115 alkyl carbamoyl group Chemical group 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000005311 halosulfanyl group Chemical group 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- -1 nitro, hydroxyl Chemical group 0.000 abstract 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 4
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 125000000446 sulfanediyl group Chemical group *S* 0.000 abstract 3
- 125000004750 (C1-C6) alkylaminosulfonyl group Chemical group 0.000 abstract 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 2
- 125000005915 C6-C14 aryl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 2
- 150000001721 carbon Chemical group 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 abstract 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 1
- 102100038417 Cytoplasmic FMR1-interacting protein 1 Human genes 0.000 abstract 1
- 101710181791 Cytoplasmic FMR1-interacting protein 1 Proteins 0.000 abstract 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31258810P | 2010-03-10 | 2010-03-10 | |
| US41560210P | 2010-11-19 | 2010-11-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR081315A1 true AR081315A1 (es) | 2012-08-08 |
Family
ID=44065466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110100737A AR081315A1 (es) | 2010-03-10 | 2011-03-09 | Derivados heterociclicos de piperidin y pirimidin -4-il-azetidina, una forma cristalina de la sal del acido acetonitriladipico de un derivado pirimidinico, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades relacionadas con la inhibicion de jak-1, t |
Country Status (37)
Families Citing this family (133)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2474545B1 (en) | 2005-12-13 | 2016-11-09 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
| CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| DK2173752T4 (en) | 2007-06-13 | 2022-08-01 | Incyte Holdings Corp | Salte af janus-kinase-inhibitor (r)-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropannitril |
| CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| JOP20190230A1 (ar) | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
| TWI484962B (zh) * | 2009-05-22 | 2015-05-21 | Incyte Corp | 作為ｊａｋ抑制劑之３－〔４－（７ｈ－吡咯并〔２，３－ｄ〕嘧啶－４－基）－１ｈ－吡唑－１－基〕辛烷或庚腈 |
| CA2762174C (en) * | 2009-05-22 | 2018-02-20 | Incyte Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| AR077280A1 (es) | 2009-06-29 | 2011-08-17 | Incyte Corp | Pirimidinonas como inhibidores de pi3k, y composiciones farmaceuticas que los comprenden |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| ME02386B (me) * | 2010-03-10 | 2016-09-20 | Incyte Holdings Corp | Derivati piperidin-4-il azetidina kao inhibitori jak1 |
| SG185567A1 (en) | 2010-05-21 | 2012-12-28 | Incyte Corp | Topical formulation for a jak inhibitor |
| US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
| US8933085B2 (en) | 2010-11-19 | 2015-01-13 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
| ES2764848T3 (es) | 2010-12-20 | 2020-06-04 | Incyte Holdings Corp | N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K |
| PT2675451E (pt) | 2011-02-18 | 2015-10-16 | Incyte Corp | Terapia de combinação com inibidores mtor/jak |
| BR112013032720A2 (pt) | 2011-06-20 | 2016-09-13 | Incyte Corp | "derivados de azetidinil fenil, piridil ou pirazinil carboxamida como inibidores de jak, composição e uso dos referidos derivados" |
| US9358229B2 (en) | 2011-08-10 | 2016-06-07 | Novartis Pharma Ag | JAK PI3K/mTOR combination therapy |
| TW201313721A (zh) * | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| IL299533B2 (en) | 2011-09-02 | 2025-01-01 | Incyte Holdings Corp | Heterocycloamines as PI3K inhibitors |
| UA111854C2 (uk) * | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| AU2012312303B2 (en) | 2011-09-22 | 2016-09-15 | Merck Sharp & Dohme Corp. | Cyanomethylpyrazole carboxamides as janus kinase inhibitors |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| AR091079A1 (es) | 2012-05-18 | 2014-12-30 | Incyte Corp | Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak |
| EA030698B1 (ru) | 2012-10-02 | 2018-09-28 | Эпитерапьютикс Апс | Ингибиторы деметилаз гистонов |
| PE20151141A1 (es) | 2012-11-01 | 2015-08-06 | Incyte Corp | Derivados triciclicos fusionados de tiofeno como inhibidores de jak |
| TW202228704A (zh) | 2012-11-15 | 2022-08-01 | 美商英塞特控股公司 | 盧梭利替尼之緩釋性劑型 |
| EP2943485B1 (en) | 2013-01-14 | 2017-09-20 | Incyte Holdings Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| AU2014207691B2 (en) | 2013-01-15 | 2018-08-30 | Incyte Holdings Corporation | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors |
| SG11201506717UA (en) | 2013-02-27 | 2015-09-29 | Epitherapeutics Aps | Inhibitors of histone demethylases |
| PT3489239T (pt) | 2013-03-06 | 2021-12-17 | Incyte Holdings Corp | Processos e intermediários para a preparação de um inibidor de jak |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| FI2970101T4 (fi) | 2013-03-14 | 2025-11-24 | Alkermes Pharma Ireland Limited | Fumaraattien aihiolääkkeitä ja niiden käyttö erilaisten sairauksien hoidossa |
| WO2014146246A1 (en) | 2013-03-19 | 2014-09-25 | Merck Sharp & Dohme Corp. | Cycloalkyl nitrile pyrazolo pyridones as janus kinase inhibitors |
| WO2014146492A1 (en) | 2013-03-19 | 2014-09-25 | Merck Sharp & Dohme Corp. | N-(2-cyano heterocyclyl)pyrazolo pyridones as janus kinase inhibitors |
| WO2014146249A1 (en) * | 2013-03-19 | 2014-09-25 | Merck Sharp & Dohme Corp. | Geminally substituted cyanoethylpyrazolo pyridones as janus kinase inhibitors |
| CN105121444B (zh) | 2013-03-19 | 2018-02-16 | 默沙东公司 | 作为janus激酶抑制剂的非环形的氰基乙基吡唑并吡啶酮 |
| US20160045498A1 (en) * | 2013-04-04 | 2016-02-18 | The Walter And Eliza Hall Institute Of Medical Research | Methods of treating diseases characterized by excessive wnt signalling |
| KR102729910B1 (ko) | 2013-05-17 | 2024-11-15 | 인사이트 홀딩스 코포레이션 | Ｊａｋ 저해제로서 비피라졸 유도체 |
| MY203694A (en) * | 2013-08-07 | 2024-07-14 | Incyte Holdings Corp | Sustained release dosage forms for a jak1 inhibitor |
| WO2015026818A1 (en) * | 2013-08-20 | 2015-02-26 | Incyte Corporation | Survival benefit in patients with solid tumors with elevated c-reactive protein levels |
| EP3036238A1 (en) | 2013-08-23 | 2016-06-29 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
| JP6367545B2 (ja) * | 2013-12-17 | 2018-08-01 | コンサート ファーマシューティカルズ インコーポレイテッド | ルキソリチニブの重水素化誘導体 |
| US9604922B2 (en) | 2014-02-24 | 2017-03-28 | Alkermes Pharma Ireland Limited | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases |
| KR20160136323A (ko) * | 2014-02-28 | 2016-11-29 | 인사이트 코포레이션 | 골수형성이상증후군 치료용 jak1 억제제 |
| DK3129021T3 (da) * | 2014-04-08 | 2020-11-09 | Incyte Corp | Behandling af b-celle-maligniteter ved en kombination af jak- og pi3k-inhibitorer |
| SG11201609016VA (en) | 2014-04-30 | 2016-11-29 | Incyte Corp | Processes of preparing a jak1 inhibitor and new forms thereto |
| US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
| US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| JP2017526675A (ja) * | 2014-08-27 | 2017-09-14 | ギリアード サイエンシーズ， インコーポレイテッド | ヒストンデメチラーゼを阻害するための化合物および方法 |
| US9586949B2 (en) | 2015-02-09 | 2017-03-07 | Incyte Corporation | Aza-heteroaryl compounds as PI3K-gamma inhibitors |
| SG11201706917WA (en) | 2015-02-27 | 2017-09-28 | Incyte Corp | Salts of pi3k inhibitor and processes for their preparation |
| US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| US9840503B2 (en) | 2015-05-11 | 2017-12-12 | Incyte Corporation | Heterocyclic compounds and uses thereof |
| WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
| US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
| WO2017013270A1 (en) | 2015-07-23 | 2017-01-26 | Universite De Strasbourg | Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy |
| WO2017027717A1 (en) | 2015-08-12 | 2017-02-16 | Incyte Corporation | Bicyclic fused pyrimidine compounds as tam inhibitors |
| US10053465B2 (en) | 2015-08-26 | 2018-08-21 | Incyte Corporation | Pyrrolopyrimidine derivatives as TAM inhibitors |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| US12365689B2 (en) | 2015-10-16 | 2025-07-22 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| JP6770775B2 (ja) | 2015-10-16 | 2020-10-21 | アッヴィ・インコーポレイテッド | （３Ｓ，４Ｒ）−３−エチル−４−（３Ｈ−イミダゾ［１，２−ａ］ピロロ［２，３−ｅ］−ピラジン−８−イル）−Ｎ−（２，２，２−トリフルオロエチル）ピロリジン−１−カルボキサミドおよびそれの固体型の製造方法 |
| US11773106B2 (en) | 2015-10-16 | 2023-10-03 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| WO2017079519A1 (en) | 2015-11-06 | 2017-05-11 | Incyte Corporation | Heterocyclic compounds as pi3k-gamma inhibitors |
| EP3360878B9 (en) * | 2015-12-11 | 2021-05-05 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Azetidine derivative, preparation method therefor, and use thereof |
| US20170190689A1 (en) | 2016-01-05 | 2017-07-06 | Incyte Corporation | Pyridine and pyridimine compounds as pi3k-gamma inhibitors |
| US10822339B2 (en) * | 2016-01-26 | 2020-11-03 | Hangzhou Huadong Medicine Group Biopharmaceutical Co. Ltd | Pyrrolopyrimidine five-membered azacyclic derivative and application thereof |
| EP3433615A1 (en) | 2016-03-21 | 2019-01-30 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods for diagnosis and treatment of solar lentigo |
| HRP20231614T1 (hr) | 2016-03-28 | 2024-03-15 | Incyte Corporation | Spojevi pirolotriazina kao tam inhibitori |
| US10138248B2 (en) | 2016-06-24 | 2018-11-27 | Incyte Corporation | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors |
| WO2018035569A1 (en) | 2016-08-24 | 2018-03-01 | Rmit University | Diagnostic methods and device |
| GB201617871D0 (en) * | 2016-10-21 | 2016-12-07 | Sareum Limited | Pharmaceutical compounds |
| US20180153922A1 (en) | 2016-12-06 | 2018-06-07 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Inhibition of expansion and function of pathogenic age-associated b cells and use for the prevention and treatment of autoimmune disease |
| PT3571192T (pt) | 2017-01-17 | 2023-02-21 | Astrazeneca | Inibidores seletivos de jak1 |
| WO2018167283A1 (en) | 2017-03-17 | 2018-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling |
| CN109422753B (zh) * | 2017-09-03 | 2021-12-31 | 上海美志医药科技有限公司 | 一类具有抑制并降解酪氨酸蛋白激酶jak1或jak2活性的化合物 |
| WO2019067594A1 (en) | 2017-09-27 | 2019-04-04 | Incyte Corporation | SALTS OF PYRROLOTRIAZINE DERIVATIVES USEFUL AS TAM INHIBITORS |
| MA50398B1 (fr) | 2017-10-18 | 2021-10-29 | Incyte Corp | Dérivés d'imidazole condensés, substitués par des groupes hydroxy tertiaires, utilisés comme inhibiteurs de pi3k-gamma |
| CN109867676B (zh) * | 2017-12-01 | 2020-10-30 | 北京普祺医药科技有限公司 | 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途 |
| TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
| CN111971279B (zh) | 2018-01-26 | 2025-09-09 | 拉普特医疗公司 | 趋化因子受体调节剂及其用途 |
| PL3746429T3 (pl) * | 2018-01-30 | 2022-06-20 | Incyte Corporation | Procesy do otrzymywania (1-(3-fluoro-2-(trifluorometylo)izonikotynoilo)piperydyn-4-onu) |
| KR102830476B1 (ko) | 2018-02-16 | 2025-07-08 | 인사이트 코포레이션 | 사이토카인-관련 장애의 치료를 위한 jak1 경로 억제제 |
| KR20210003086A (ko) | 2018-03-08 | 2021-01-11 | 노파르티스 아게 | 항-p-셀렉틴 항체의 용도 |
| US11584961B2 (en) | 2018-03-30 | 2023-02-21 | Incyte Corporation | Biomarkers for inflammatory skin disease |
| RS65624B1 (sr) * | 2018-03-30 | 2024-07-31 | Incyte Corp | Lečenje supurativnog hidradenitisa upotrebom jak inhbitora |
| EP3775923A1 (en) | 2018-04-13 | 2021-02-17 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| SG11202011680YA (en) | 2018-06-01 | 2020-12-30 | Incyte Corp | Dosing regimen for the treatment of pi3k related disorders |
| MX2021000127A (es) | 2018-06-29 | 2021-03-29 | Incyte Corp | Formulaciones de un inhibidor de axl/mer. |
| WO2020039401A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | Treatment comprising il-1βeta binding antibodies and combinations thereof |
| CR20250050A (es) | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
| IL282643B2 (en) | 2018-10-31 | 2025-08-01 | Incyte Corp | A selective jak1 inhibitor for use in a method of treating hematological disease |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| KR101992148B1 (ko) | 2018-11-30 | 2019-06-25 | 한승훈 | 안전벨트의 꼬임방지장치 |
| US11596632B2 (en) | 2018-12-19 | 2023-03-07 | Incyte Corporation | JAK1 pathway inhibitors for the treatment of gastrointestinal disease |
| CN113242859B (zh) * | 2018-12-24 | 2023-04-14 | 正大天晴药业集团股份有限公司 | 吡咯并嘧啶化合物的治疗用途及其固体药物组合物 |
| EA202192426A1 (ru) | 2019-03-05 | 2021-11-15 | Инсайт Корпорейшн | Ингибиторы путей jak1 для лечения хронической дисфункции аллотрансплантата легких |
| EP3939979A4 (en) | 2019-03-14 | 2022-04-06 | Shanghai Synergy Pharmaceutical Sciences Co., Ltd | Jak kinase inhibitor, preparation method for same, and applications thereof in field of medicine |
| TW202102222A (zh) | 2019-03-19 | 2021-01-16 | 美商英塞特公司 | 白斑病之生物標記物 |
| WO2021091535A1 (en) | 2019-11-05 | 2021-05-14 | Constellation Pharmaceuticals, Inc. | Treating myeloproliferative disorders with cpi-0610 and a jak inhibitor |
| WO2020257644A1 (en) | 2019-06-21 | 2020-12-24 | Constellation Pharmaceuticals, Inc. | Methods of treating myeloproliferative disorders |
| WO2020256739A1 (en) | 2019-06-21 | 2020-12-24 | Constellation Pharmaceuticals, Inc. | Methods of treating myeloproliferative disorders |
| WO2021053490A1 (en) | 2019-09-16 | 2021-03-25 | Novartis Ag | Use of high-affinity, ligand-blocking, humanized anti-t-cell immunoglobulin domain and mucin domain-3 (tim-3) igg4 antibody for the treatment of myelofibrosis |
| US20220331318A1 (en) | 2019-09-16 | 2022-10-20 | Novartis Ag | Use of an mdm2 inhibitor for the treatment of myelofibrosis |
| CA3156007A1 (en) | 2019-09-27 | 2021-04-01 | Disc Medicine, Inc. | METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS |
| EP4041204A1 (en) | 2019-10-10 | 2022-08-17 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| WO2021072098A1 (en) | 2019-10-10 | 2021-04-15 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
| WO2021076124A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp) |
| PH12022551052A1 (en) | 2019-11-22 | 2023-05-29 | Incyte Corp | Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor |
| MX2022010860A (es) | 2020-03-06 | 2022-12-02 | Incyte Corp | Terapia combinada que comprende inhibidores de axl/mer y pd-1/pd-l1. |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| HRP20241560T1 (hr) | 2020-06-02 | 2025-01-17 | Incyte Corporation | Postupci za proizvodnju inhibitora jak1 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| AU2021329301A1 (en) | 2020-08-18 | 2023-04-13 | Incyte Corporation | Process and intermediates for preparing a JAK1 inhibitor |
| JP2023539126A (ja) | 2020-08-18 | 2023-09-13 | インサイト・コーポレイション | Ｊａｋ阻害剤を調製するための方法及び中間体 |
| EP4225317A1 (en) | 2020-10-08 | 2023-08-16 | Novartis AG | Use of an erk inhibitor for the treatment of myelofibrosis |
| US12005067B2 (en) | 2020-12-04 | 2024-06-11 | Incyte Corporation | JAK inhibitor with a vitamin D analog for treatment of skin diseases |
| KR20230118118A (ko) | 2020-12-08 | 2023-08-10 | 인사이트 코포레이션 | 백반증의 치료를 위한 jak1 경로 저해제 |
| JP2024503021A (ja) | 2021-01-11 | 2024-01-24 | インサイト・コーポレイション | Ｊａｋ経路阻害剤及びｒｏｃｋ阻害剤を含む併用療法 |
| TW202402754A (zh) | 2021-03-04 | 2024-01-16 | 美商美國禮來大藥廠 | Fgfr3抑制劑化合物 |
| CN117098765A (zh) * | 2021-03-15 | 2023-11-21 | 奇斯药制品公司 | 作为詹纳斯激酶抑制剂的杂环衍生物 |
| US12268667B2 (en) | 2021-05-03 | 2025-04-08 | Incyte Corporation | JAK1 pathway inhibitors for the treatment of prurigo nodularis |
| CA3226714A1 (en) | 2021-07-12 | 2023-01-19 | Incyte Corporation | Process and intermediates for preparing baricitinib |
| CN114149437A (zh) * | 2021-12-24 | 2022-03-08 | 安徽大学 | 一种吡咯并嘧啶五元氮杂环衍生物及其制备方法和用途 |
| MA71694A (fr) | 2022-08-05 | 2025-05-30 | Incyte Corporation | Traitement de l'urticaire au moyen d'inhibiteurs de jak |
| WO2024192350A1 (en) | 2023-03-16 | 2024-09-19 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of asthma |
| WO2024222835A1 (en) * | 2023-04-27 | 2024-10-31 | Sironax Ltd. | Sarm1 modulators, preparations, and uses thereof |
| US20250325664A1 (en) | 2024-04-22 | 2025-10-23 | Incyte Corporation | Combination therapy with an anti-colony stimulating factor 1 receptor antibody and a jak inhibitor |
Family Cites Families (309)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2985589A (en) * | 1957-05-22 | 1961-05-23 | Universal Oil Prod Co | Continuous sorption process employing fixed bed of sorbent and moving inlets and outlets |
| US3632836A (en) | 1968-10-25 | 1972-01-04 | Dow Chemical Co | Solid curable polyepoxides modified with hydrolyzed liquid polyepoxides |
| US3832460A (en) | 1971-03-19 | 1974-08-27 | C Kosti | Anesthetic-vasoconstrictor-antihistamine composition for the treatment of hypertrophied oral tissue |
| US4140755A (en) | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
| DE3036390A1 (de) | 1980-09-26 | 1982-05-13 | Troponwerke GmbH & Co KG, 5000 Köln | Neue pyrrolo-pyrimidine, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung von biologischen wirkstoffen |
| DE3220113A1 (de) * | 1982-05-28 | 1983-12-01 | Basf Ag, 6700 Ludwigshafen | Difluormethoxiphenylthiophosphorsaeureester |
| US4402832A (en) * | 1982-08-12 | 1983-09-06 | Uop Inc. | High efficiency continuous separation process |
| US4404335A (en) | 1982-08-16 | 1983-09-13 | The Dow Chemical Company | Hydrolyzing epoxy resins in absence of solvent and in presence of oxalic acid and a phosphonium compound |
| US4548990A (en) | 1983-08-15 | 1985-10-22 | Ciba-Geigy Corporation | Crosslinked, porous polymers for controlled drug delivery |
| US4498991A (en) * | 1984-06-18 | 1985-02-12 | Uop Inc. | Serial flow continuous separation process |
| NL8403224A (nl) * | 1984-10-24 | 1986-05-16 | Oce Andeno Bv | Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen. |
| CA1306260C (en) | 1985-10-18 | 1992-08-11 | Shionogi & Co., Ltd. | Condensed imidazopyridine derivatives |
| JPH0710876Y2 (ja) | 1989-08-31 | 1995-03-15 | 石垣機工株式会社 | スクリュープレスにおける脱水筒の洗浄装置 |
| JP2541702B2 (ja) * | 1989-10-11 | 1996-10-09 | 帝人株式会社 | 二環性ピリミジン誘導体、その製造方法およびそれを有効成分とする医薬製剤 |
| US5403593A (en) | 1991-03-04 | 1995-04-04 | Sandoz Ltd. | Melt granulated compositions for preparing sustained release dosage forms |
| IT1258781B (it) * | 1992-01-16 | 1996-02-29 | Zambon Spa | Composizione farmaceutica oftalmica contenente n-acetilcisteina e polivinilalcol |
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| FR2695126B1 (fr) | 1992-08-27 | 1994-11-10 | Sanofi Elf | Dérivés d'acide thiényl ou pyrrolyl carboxyliques, leur préparation et médicaments les contenant. |
| AU671491B2 (en) | 1992-12-18 | 1996-08-29 | F. Hoffmann-La Roche Ag | N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines |
| JPH0710876A (ja) | 1993-06-24 | 1995-01-13 | Teijin Ltd | ４位に環状アミノ基を有するピロロ［２，３―ｄ］ピリミジン |
| USH1439H (en) | 1993-10-18 | 1995-05-02 | The Dow Chemical Company | Method to increase the level of α-glycol in liquid epoxy resin |
| EP0727217A3 (en) | 1995-02-10 | 1997-01-15 | Suntory Ltd | Pharmaceutical and cosmetic compositions containing God-type ellagitannin as an active ingredient |
| US5856326A (en) * | 1995-03-29 | 1999-01-05 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| IL117580A0 (en) | 1995-03-29 | 1996-07-23 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them |
| PL324486A1 (en) | 1995-07-05 | 1998-05-25 | Du Pont | Fungicidal pyrimidinones |
| KR100437582B1 (ko) | 1995-07-06 | 2004-12-17 | 노파르티스 아게 | 피롤로피리미딘및그들의제조방법 |
| US5630943A (en) * | 1995-11-30 | 1997-05-20 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Discontinuous countercurrent chromatographic process and apparatus |
| GB9604361D0 (en) | 1996-02-29 | 1996-05-01 | Pharmacia Spa | 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors |
| JP2000504023A (ja) | 1996-04-03 | 2000-04-04 | メルク エンド カンパニー インコーポレーテッド | 癌治療方法 |
| WO1997038664A2 (en) | 1996-04-18 | 1997-10-23 | Merck & Co., Inc. | A method of treating cancer |
| US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| WO1997045412A1 (en) | 1996-05-30 | 1997-12-04 | Merck & Co., Inc. | A method of treating cancer |
| US6624138B1 (en) | 2001-09-27 | 2003-09-23 | Gp Medical | Drug-loaded biological material chemically treated with genipin |
| CA2286239A1 (en) | 1997-04-07 | 1998-10-15 | Merck & Co., Inc. | A method of treating cancer |
| US6063284A (en) | 1997-05-15 | 2000-05-16 | Em Industries, Inc. | Single column closed-loop recycling with periodic intra-profile injection |
| US6060038A (en) * | 1997-05-15 | 2000-05-09 | Merck & Co., Inc. | Radiolabeled farnesyl-protein transferase inhibitors |
| CA2295620A1 (en) * | 1997-08-11 | 1999-02-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | 5,6-heteroaryl-dipyrido¬2,3-b:3',2'-f|azepines and their use in the prevention or treatment of hiv infection |
| US7153845B2 (en) | 1998-08-25 | 2006-12-26 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
| US6075056A (en) | 1997-10-03 | 2000-06-13 | Penederm, Inc. | Antifungal/steroid topical compositions |
| US6025366A (en) | 1998-04-02 | 2000-02-15 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| JP2002517396A (ja) | 1998-06-04 | 2002-06-18 | アボット・ラボラトリーズ | 細胞接着阻害抗炎症性化合物 |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| JP4666762B2 (ja) | 1998-06-19 | 2011-04-06 | ファイザー・プロダクツ・インク | ピロロ［２．３−ｄ］ピリミジン化合物 |
| WO2000009495A1 (en) | 1998-08-11 | 2000-02-24 | Novartis Ag | Isoquinoline derivatives with angiogenesis inhibiting activity |
| JP2000119271A (ja) | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | １ｈ―イミダゾピリジン誘導体 |
| TR200100708T2 (tr) | 1998-09-10 | 2001-07-23 | Nycomed Danmark A/S | İlaç maddelerine mahsus çabuk salımlı farmasötik bileşimler. |
| FR2785196B1 (fr) | 1998-10-29 | 2000-12-15 | Inst Francais Du Petrole | Procede et dispositif de separation avec des zones chromatographiques a longueur variable |
| US6375839B1 (en) * | 1998-10-29 | 2002-04-23 | Institut Francais Du Petrole | Process and device for separation with variable-length chromatographic zones |
| US6413419B1 (en) * | 1998-10-29 | 2002-07-02 | Institut Francais Du Petrole | Process and device for separation with variable-length chromatographic |
| US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
| WO2000051614A1 (en) | 1999-03-03 | 2000-09-08 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferases |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| US6217895B1 (en) * | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
| US6239113B1 (en) * | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
| WO2000063168A1 (en) | 1999-04-16 | 2000-10-26 | Coelacanth Chemical Corporation | Synthesis of azetidine derivatives |
| US6915718B2 (en) * | 1999-09-02 | 2005-07-12 | United Parts Fhs Automobil Systeme Gmbh | Selector handle in a motor vehicle |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| ATE275141T1 (de) * | 1999-10-13 | 2004-09-15 | Banyu Pharma Co Ltd | Substituierte imidazolin-derivate |
| US7235258B1 (en) | 1999-10-19 | 2007-06-26 | Nps Pharmaceuticals, Inc. | Sustained-release formulations for treating CNS-mediated disorders |
| DK1235830T3 (da) | 1999-12-10 | 2004-03-29 | Pfizer Prod Inc | Pyrrolo[2,3-d]pyrimidin-forbindelser som proteinkinaseinhibitorer |
| AP1917A (en) | 1999-12-24 | 2008-11-12 | Aventis Pharma Ltd | Azaindoles |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| US7235551B2 (en) * | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
| DE60100866T2 (de) | 2000-04-07 | 2004-07-29 | Laboratoire Medidom S.A. | Cyklosporin, Hyaluronsäure und Polysorbate enthaltenes Augenarzneimittel |
| WO2001081345A1 (en) | 2000-04-20 | 2001-11-01 | Mitsubishi Pharma Corporation | Aromatic amide compounds |
| ES2567260T3 (es) | 2000-04-25 | 2016-04-21 | Icos Corporation | Inhibidores de la fosfatidilinositol 3-quinasa delta humana |
| US7498304B2 (en) * | 2000-06-16 | 2009-03-03 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
| CA2412215A1 (en) | 2000-06-16 | 2001-12-27 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
| US6335342B1 (en) | 2000-06-19 | 2002-01-01 | Pharmacia & Upjohn S.P.A. | Azaindole derivatives, process for their preparation, and their use as antitumor agents |
| ES2344831T3 (es) * | 2000-06-23 | 2010-09-08 | Mitsubishi Tanabe Pharma Corporation | Potenciadores de un efecto antitumoral. |
| AU784297C (en) | 2000-06-26 | 2007-01-11 | Pfizer Products Inc. | Pyrrolo(2,3-d)pyrimidine compounds as immunosuppressive agents |
| PL202623B1 (pl) | 2000-06-28 | 2009-07-31 | Smithkline Beecham Plc | Sposób wytwarzania drobno zmielonego preparatu substancji leczniczej, drobno zmielona substancja lecznicza wytworzona tym sposobem i zawierająca ją kompozycja farmaceutyczna |
| AU2001278790A1 (en) | 2000-08-22 | 2002-03-04 | Hokuriku Seiyaku Co. Ltd | 1h-imidazopyridine derivatives |
| CA2430539C (en) | 2000-12-05 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| GB0100622D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds V111 |
| JP2004520347A (ja) * | 2001-01-15 | 2004-07-08 | グラクソ グループ リミテッド | Ｌｄｌ−受容体発現のインデューサーとしてのアリールピペリジンおよびピペラジン誘導体 |
| US20040102455A1 (en) | 2001-01-30 | 2004-05-27 | Burns Christopher John | Method of inhibiting kinases |
| WO2002092573A2 (en) | 2001-05-16 | 2002-11-21 | Vertex Pharmaceuticals Incorporated | Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases |
| US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
| GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| GB0115393D0 (en) | 2001-06-23 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| CA2455181C (en) * | 2001-08-01 | 2010-04-06 | Merck & Co., Inc. | Benzimidazo[4,5-f]isoquinolinone derivatives |
| DE60230890D1 (de) | 2001-09-19 | 2009-03-05 | Aventis Pharma Sa | Indolizine als kinaseproteinhemmer |
| US6429231B1 (en) | 2001-09-24 | 2002-08-06 | Bradley Pharmaceuticals, Inc. | Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use |
| MXPA04004137A (es) | 2001-10-30 | 2005-01-25 | Novartis Ag | Derivados de estauroesporina como inhibidores de la actividad de cinasa de tirosina del receptor flt3. |
| JP2003155285A (ja) | 2001-11-19 | 2003-05-27 | Toray Ind Inc | 環状含窒素誘導体 |
| AU2002224131A1 (en) | 2001-11-30 | 2003-06-17 | Teijin Limited | Process for producing 5-(3-cyanophenyl)-3-formylbenzoic acid compound |
| GT200200234A (es) | 2001-12-06 | 2003-06-27 | Compuestos cristalinos novedosos | |
| US6995144B2 (en) * | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
| EP1503739A4 (en) | 2002-04-15 | 2006-06-21 | Adams Respiratory Therapeutics | REGULAR RELEASE OF COMBINED MEDICINAL PRODUCTS FROM GUAIFENESIN |
| TW200403058A (en) * | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| US7304061B2 (en) * | 2002-04-26 | 2007-12-04 | Vertex Pharmaceuticals Incorporated | Heterocyclic inhibitors of ERK2 and uses thereof |
| JP2005530745A (ja) | 2002-05-02 | 2005-10-13 | メルク エンド カムパニー インコーポレーテッド | チロシンキナーゼ阻害剤 |
| BR0309844A (pt) * | 2002-05-07 | 2005-02-15 | Control Delivery Sys Inc | Processos para formação de um dispositivo para a distribuição de droga |
| CN100558715C (zh) | 2002-05-23 | 2009-11-11 | 西托匹亚有限公司 | 蛋白激酶抑制剂 |
| TW200406374A (en) | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
| CA2490340A1 (en) | 2002-06-26 | 2004-01-08 | Idemitsu Kosan Co., Ltd. | Hydrogenated copolymer, production process for the same and hot melt adhesive composition using the same |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| GB0215844D0 (en) * | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
| US20060004010A1 (en) * | 2002-07-10 | 2006-01-05 | Hiromu Habashita | Ccr4 antagonist and medical use thereof |
| CA2497977A1 (en) | 2002-09-20 | 2004-04-01 | Alcon, Inc. | Use of cytokine synthesis inhibitors for the treatment of dry eye disorders |
| US20040204404A1 (en) | 2002-09-30 | 2004-10-14 | Robert Zelle | Human N-type calcium channel blockers |
| ES2289349T3 (es) | 2002-11-04 | 2008-02-01 | Vertex Pharmaceuticals Incorporated | Derivados de heteroaril-pirimidina como inhibidores de jak. |
| US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
| US20040099204A1 (en) | 2002-11-25 | 2004-05-27 | Nestor John J. | Sheet, page, line, position marker |
| PL378246A1 (pl) | 2002-11-26 | 2006-03-20 | Pfizer Products Inc. | Sposób leczenia odrzucania przeszczepu |
| UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| TWI335819B (en) * | 2002-12-24 | 2011-01-11 | Alcon Inc | Use of oculosurface selective glucocorticoid in the treatment of dry eye |
| TW200418806A (en) | 2003-01-13 | 2004-10-01 | Fujisawa Pharmaceutical Co | HDAC inhibitor |
| US7167750B2 (en) | 2003-02-03 | 2007-01-23 | Enteromedics, Inc. | Obesity treatment with electrically induced vagal down regulation |
| EP1611125A1 (en) | 2003-02-07 | 2006-01-04 | Vertex Pharmaceuticals Incorporated | Heteroaryl substituted pyrolls useful as inhibitors of protein kinases |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| US7547794B2 (en) | 2003-04-03 | 2009-06-16 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| SE0301372D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| SE0301373D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| FR2857454B1 (fr) | 2003-07-08 | 2006-08-11 | Aventis Pasteur | Dosage des acides techoiques des bacteries gram+ |
| US20050043346A1 (en) | 2003-08-08 | 2005-02-24 | Pharmacia Italia S.P.A. | Pyridylpyrrole derivatives active as kinase inhibitors |
| JP5010917B2 (ja) | 2003-08-29 | 2012-08-29 | エグゼリクシス， インコーポレイテッド | ｃ−Ｋｉｔ調節因子および使用方法 |
| US8084457B2 (en) | 2003-09-15 | 2011-12-27 | Lead Discovery Center Gmbh | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
| ES2357801T3 (es) * | 2003-10-24 | 2011-04-29 | Santen Pharmaceutical Co., Ltd. | Agente terapéutico para trastorno queratoconjuntival. |
| US7387793B2 (en) | 2003-11-14 | 2008-06-17 | Eurand, Inc. | Modified release dosage forms of skeletal muscle relaxants |
| MY141220A (en) | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
| CA2545192A1 (en) | 2003-11-25 | 2005-06-09 | Pfizer Products Inc. | Method of treatment of atherosclerosis |
| BRPI0417803A (pt) | 2003-12-17 | 2007-04-10 | Pfizer Prod Inc | método de tratamento de rejeição de transplantes |
| ATE406356T1 (de) | 2003-12-19 | 2008-09-15 | Schering Corp | Thiadiazole als cxc- und cc- chemokinrezeptorliganden |
| SI1696920T1 (sl) | 2003-12-19 | 2015-02-27 | Plexxikon Inc. | Spojine in postopki za razvoj modulatorjev ret |
| BRPI0418078A8 (pt) | 2003-12-23 | 2018-01-02 | Astex Therapeutics Ltd | composto ou um seu sal, solvato, tautômero ou n-óxido, uso de um composto, métodos para a profilaxia ou tratamento de um estado ou condição doentia mediada pela proteína quinase b e mediada pela proteína quinase a, para tratar uma doença ou condição, para inibir uma proteína quinase b e uma proteína quinase a, para modular um processo celular, para tratar um distúrbio imune em um mamífero e para induzir apoptose em uma célula cancerosa, composição farmacêutica, e, processo para a preparação de um composto |
| US20050153989A1 (en) * | 2004-01-13 | 2005-07-14 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
| WO2005089502A2 (en) | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| BRPI0509369B1 (pt) | 2004-03-30 | 2021-08-03 | Vertex Pharmaceuticals Incorporated | Compostos azaindóis úteis como inibidores de jak e outras proteína cinases e composição farmacêutica |
| US8076338B2 (en) | 2004-04-23 | 2011-12-13 | Exelixis, Inc. | Kinase modulators and methods of use |
| WO2005105988A2 (en) | 2004-04-28 | 2005-11-10 | Vertex Pharmaceuticals Incorporated | Crystal structure of human jak3 kinase domain complex and binding pockets thereof |
| US20060106020A1 (en) * | 2004-04-28 | 2006-05-18 | Rodgers James D | Tetracyclic inhibitors of Janus kinases |
| BRPI0510627A (pt) | 2004-05-03 | 2007-10-30 | Novartis Ag | combinações que compreendem um agonista do receptor s1p e um inibidor da jak3 quinase |
| US20060074102A1 (en) | 2004-05-14 | 2006-04-06 | Kevin Cusack | Kinase inhibitors as therapeutic agents |
| PE20060426A1 (es) | 2004-06-02 | 2006-06-28 | Schering Corp | DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa |
| WO2005123719A1 (en) | 2004-06-10 | 2005-12-29 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| EP1760071A4 (en) * | 2004-06-23 | 2008-03-05 | Ono Pharmaceutical Co | COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF |
| WO2006004984A1 (en) | 2004-06-30 | 2006-01-12 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of protein kinases |
| US7138423B2 (en) | 2004-07-20 | 2006-11-21 | Bristol-Myers Squibb Company | Arylpyrrolidine derivatives as NK-1 /SSRI antagonists |
| FR2873691B1 (fr) | 2004-07-29 | 2006-10-06 | Sanofi Synthelabo | Derives d'amino-piperidine, leur preparation et leur application en therapeutique |
| WO2006013114A1 (en) | 2004-08-06 | 2006-02-09 | Develogen Aktiengesellschaft | Use of a timp-2 secreted protein product for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome |
| WO2006022459A1 (en) | 2004-08-23 | 2006-03-02 | Mogam Biotechnology Institute | Primer and probe for detection of sars coronavirus, kit comprising the primer and/or the probe, and detection method thereof |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| WO2006040036A1 (en) * | 2004-10-13 | 2006-04-20 | F. Hoffmann-La Roche Ag | Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| DK1812440T3 (da) | 2004-11-04 | 2011-01-31 | Vertex Pharma | Pyrazolo[1,5-a]pyrimidiner, der kan anvendes som inhibistorer af proteinkinaser |
| BRPI0517887A (pt) | 2004-11-24 | 2008-10-21 | Novartis Ag | combinações de inibidores de jaks |
| US7517870B2 (en) * | 2004-12-03 | 2009-04-14 | Fondazione Telethon | Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization |
| WO2006065916A1 (en) * | 2004-12-14 | 2006-06-22 | Alcon, Inc. | Method of treating dry eye disorders using 13(s)-hode and its analogs |
| AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| TW200635899A (en) | 2004-12-22 | 2006-10-16 | Astrazeneca Ab | Chemical compounds |
| CA2595574A1 (en) | 2005-01-20 | 2006-07-27 | Pfizer Limited. | Chemical compounds |
| CA2596830A1 (en) | 2005-02-03 | 2006-09-14 | Vertex Pharmaceuticals Incorporated | Pyrrolopyrimidines useful as inhibitors of protein kinase |
| WO2007044050A2 (en) | 2005-02-04 | 2007-04-19 | Bristol-Myers Squibb Company | 1h-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
| JP2008533145A (ja) | 2005-03-15 | 2008-08-21 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| AU2006232105A1 (en) | 2005-04-05 | 2006-10-12 | Pharmacopeia, Inc. | Purine and imidazopyridine derivatives for immunosuppression |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| ZA200710379B (en) * | 2005-05-20 | 2009-05-27 | Vertex Pharma | Pyrrolopyridines useful as inhibitors of protein kinase |
| JP5225079B2 (ja) | 2005-06-08 | 2013-07-03 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｊａｋ経路の阻害のための組成物および方法 |
| WO2006136823A1 (en) | 2005-06-21 | 2006-12-28 | Astex Therapeutics Limited | Heterocyclic containing amines as kinase b inhibitors |
| WO2007002325A1 (en) | 2005-06-22 | 2007-01-04 | Plexxikon, Inc. | Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors |
| EP2251341A1 (en) | 2005-07-14 | 2010-11-17 | Astellas Pharma Inc. | Heterocyclic Janus kinase 3 inhibitors |
| FR2889662B1 (fr) | 2005-08-11 | 2011-01-14 | Galderma Res & Dev | Emulsion de type huile-dans-eau pour application topique en dermatologie |
| US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
| WO2007038215A1 (en) | 2005-09-22 | 2007-04-05 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
| CN101801971A (zh) | 2005-09-30 | 2010-08-11 | 沃泰克斯药物股份有限公司 | 可用作janus激酶抑制剂的脱氮嘌呤 |
| US20070128633A1 (en) | 2005-10-11 | 2007-06-07 | Chembridge Research Laboratories, Inc. | Cell-free protein expression systems and methods of use thereof |
| AU2006300182B2 (en) | 2005-10-14 | 2012-01-19 | Sumitomo Chemical Company, Limited | Hydrazide compound and pesticidal use of the same |
| US20080287475A1 (en) | 2005-10-28 | 2008-11-20 | Astrazeneca Ab | 4-(3-Aminopyrazole) Pyrimidine Derivatives for Use as Tyrosine Kinase Inhibitors in the Treatment of Cancer |
| PL1951684T3 (pl) * | 2005-11-01 | 2017-03-31 | Targegen, Inc. | Biarylowe meta-pirymidynowe inhibitory kinaz |
| PL2275103T3 (pl) | 2005-11-21 | 2014-09-30 | Novartis Ag | Inhibitory mTOR w leczeniu nowotworów neuroendokrynnych |
| WO2007062459A1 (en) | 2005-11-29 | 2007-06-07 | Cytopia Research Pty Ltd | Selective kinase inhibitors based on pyridine scaffold |
| EP2474545B1 (en) | 2005-12-13 | 2016-11-09 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
| US20130137681A1 (en) * | 2005-12-13 | 2013-05-30 | Incyte Corporation | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS |
| EP1968568A4 (en) | 2005-12-22 | 2011-04-13 | Glaxosmithkline Llc | HEMMER OF NUTS ACTIVITY |
| ES2408318T3 (es) * | 2005-12-23 | 2013-06-20 | Glaxosmithkline Llc | Inhibidores de azaindol de las cinasas Aurora |
| JP4643455B2 (ja) | 2006-01-12 | 2011-03-02 | 株式会社ユニバーサルエンターテインメント | 遊技システム |
| CN102532133A (zh) | 2006-01-17 | 2012-07-04 | 沃泰克斯药物股份有限公司 | 适用作詹纳斯激酶抑制剂的吖吲哚类 |
| WO2007084667A2 (en) * | 2006-01-19 | 2007-07-26 | Osi Pharmaceutical, Inc. | Fused heterobicyclic kinase inhibitors |
| JP2009525350A (ja) * | 2006-02-01 | 2009-07-09 | スミスクライン ビーチャム コーポレーション | Ｒａｆキナーゼ阻害薬として有用なピロロ［２，３，ｂ］ピリジン誘導体 |
| US7745477B2 (en) | 2006-02-07 | 2010-06-29 | Hoffman-La Roche Inc. | Heteroaryl and benzyl amide compounds |
| RU2008136766A (ru) | 2006-02-24 | 2010-03-27 | Тева Фармасьютикл Индастриес Лтд. (Il) | Таблетки метопролола сукцината пролонгированного действия и способы их приготовления |
| KR20090008217A (ko) * | 2006-03-10 | 2009-01-21 | 오노 야꾸힝 고교 가부시키가이샤 | 질소 함유 복소환 유도체 및 이들을 유효 성분으로 하는 약제 |
| JP5099005B2 (ja) * | 2006-04-03 | 2012-12-12 | アステラス製薬株式会社 | ヘテロ化合物 |
| RU2008143361A (ru) * | 2006-04-05 | 2010-05-10 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Деазапурины в качестве ингибиторов янус-киназ |
| US20090124636A1 (en) | 2006-04-12 | 2009-05-14 | Pfizer Inc. | Chemical compounds |
| WO2007129195A2 (en) | 2006-05-04 | 2007-11-15 | Pfizer Products Inc. | 4-pyrimidine-5-amino-pyrazole compounds |
| US20080051427A1 (en) | 2006-05-18 | 2008-02-28 | Fritz Schuckler | Pharmaceutical Compositions and Methods of Using Same |
| US7691811B2 (en) * | 2006-05-25 | 2010-04-06 | Bodor Nicholas S | Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye |
| JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
| NZ573174A (en) | 2006-06-01 | 2012-01-12 | Msd Consumer Care Inc | Sustained release pharmaceutical dosage form containing phenylephrine |
| BRPI0713187A2 (pt) * | 2006-07-20 | 2012-10-16 | Mehmet Kahraman | método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica |
| WO2008013622A2 (en) | 2006-07-27 | 2008-01-31 | E. I. Du Pont De Nemours And Company | Fungicidal azocyclic amides |
| US8492378B2 (en) * | 2006-08-03 | 2013-07-23 | Takeda Pharmaceutical Company Limited | GSK-3β inhibitor |
| ATE517868T1 (de) * | 2006-08-16 | 2011-08-15 | Boehringer Ingelheim Int | Pyrazinverbindungen, ihre verwendung und herstellungsverfahren |
| KR20090060333A (ko) | 2006-09-08 | 2009-06-11 | 노파르티스 아게 | 림프구 상호작용에 의해 매개되는 질환의 치료에 유용한 ｎ-바이아릴 (헤테로)아릴술폰아미드 유도체 |
| WO2008035376A2 (en) | 2006-09-19 | 2008-03-27 | Council Of Scientific & Industrial Research | A novel bio-erodible insert for ophthalmic applications and a process for the preparation thereof |
| TW200831104A (en) | 2006-10-04 | 2008-08-01 | Pharmacopeia Inc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| AR063141A1 (es) * | 2006-10-04 | 2008-12-30 | Pharmacopeia Inc | Derivados de 2- ( benzimidazolil ) purina 8- sustituida para inmunosupresion |
| US20120225057A1 (en) | 2006-10-11 | 2012-09-06 | Deciphera Pharmaceuticals, Llc | Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases |
| MY146474A (en) | 2006-11-06 | 2012-08-15 | Supergen Inc | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
| US20080119496A1 (en) * | 2006-11-16 | 2008-05-22 | Pharmacopeia Drug Discovery, Inc. | 7-Substituted Purine Derivatives for Immunosuppression |
| SI2497470T1 (sl) | 2006-11-22 | 2016-02-29 | Incyte Holdings Corporation | Imidazotriazini in imidazopirimidini kot inhibitorji kinaz |
| WO2008067119A2 (en) | 2006-11-27 | 2008-06-05 | Smithkline Beecham Corporation | Novel compounds |
| MX2009006304A (es) | 2006-12-15 | 2009-06-23 | Abbott Lab | Nuevos compuestos de oxadiazol. |
| CA2672438A1 (en) | 2006-12-20 | 2008-07-03 | Amgen Inc. | Substituted heterocycles and methods of use |
| MX2009006543A (es) | 2006-12-20 | 2009-06-26 | Amgen Inc | Compuestos heterociclicos y su uso en el tratamiento de la inflamacion, angiogenesis y cancer. |
| EA016795B1 (ru) | 2006-12-22 | 2012-07-30 | Сигма-Тау Индустрие Фармасьютике Риуните С.П.А. | Гель, применимый для доставки офтальмологических лекарственных средств |
| WO2008079965A1 (en) | 2006-12-22 | 2008-07-03 | Incyte Corporation | Substituted heterocycles as janus kinase inhibitors |
| WO2008082839A2 (en) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Pim kinase inhibitors as cancer chemotherapeutics |
| WO2008082840A1 (en) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Pim kinase inhibitors as cancer chemotherapeutics |
| KR20080062876A (ko) | 2006-12-29 | 2008-07-03 | 주식회사 대웅제약 | 신규한 항진균성 트리아졸 유도체 |
| JP5330274B2 (ja) | 2007-03-01 | 2013-10-30 | ノバルティス アーゲー | Ｐｉｍキナーゼ阻害剤およびその使用方法 |
| MY157724A (en) | 2007-04-03 | 2016-07-15 | Array Biopharma Inc | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS |
| US8188178B2 (en) | 2007-05-07 | 2012-05-29 | 3M Innovative Properties Company | Cold shrinkable article including an epichlorohydrin composition |
| GB0709031D0 (en) | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
| JP5603770B2 (ja) | 2007-05-31 | 2014-10-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ２受容体拮抗薬およびその使用 |
| GB0710528D0 (en) | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Novel compounds |
| CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| DK2173752T4 (en) | 2007-06-13 | 2022-08-01 | Incyte Holdings Corp | Salte af janus-kinase-inhibitor (r)-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropannitril |
| US8541426B2 (en) | 2007-07-11 | 2013-09-24 | Pfizer Inc. | Pharmaceutical compositions and methods of treating dry eye disorders |
| AP2010005167A0 (en) * | 2007-08-01 | 2010-02-28 | Pfizer | Pyrazole compounds and their use as RAF inhibitors |
| WO2009049028A1 (en) | 2007-10-09 | 2009-04-16 | Targegen Inc. | Pyrrolopyrimidine compounds and their use as janus kinase modulators |
| US20110263664A1 (en) | 2007-11-15 | 2011-10-27 | Musc Foundation For Research Development | Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer |
| KR101580482B1 (ko) | 2007-11-16 | 2015-12-28 | 인사이트 홀딩스 코포레이션 | 야누스 키나제 억제제로서의 ４－피라졸릴－ｎ－아릴피리미딘－２－아민 및 ４－피라졸릴－ｎ－헤테로아릴피리미딘－２－아민 |
| GB0723815D0 (en) | 2007-12-05 | 2008-01-16 | Glaxo Group Ltd | Compounds |
| HUE030767T2 (en) * | 2008-01-18 | 2017-05-29 | Inst Of Organic Chemistry And Biochemistry Of The Acad Of Sciences Of The Czech Republic | New, cytostatic 7-deazapurine nucleosides |
| EP2240016A4 (en) | 2008-02-04 | 2011-11-16 | Mercury Therapeutics Inc | AMPK MODULATORS |
| PE20091577A1 (es) | 2008-03-03 | 2009-11-05 | Novartis Ag | Inhibidores de cinasa pim y metodos para su uso |
| US8158616B2 (en) | 2008-03-11 | 2012-04-17 | Incyte Corporation | Azetidine and cyclobutane derivatives as JAK inhibitors |
| CA2718936A1 (en) | 2008-03-21 | 2009-09-24 | Novartis Ag | Novel heterocyclic compounds and uses therof |
| CA2727928A1 (en) | 2008-06-18 | 2009-12-23 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| WO2009158687A1 (en) | 2008-06-26 | 2009-12-30 | Anterios, Inc. | Dermal delivery |
| UY31952A (es) | 2008-07-02 | 2010-01-29 | Astrazeneca Ab | 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim |
| FR2933409B1 (fr) | 2008-07-03 | 2010-08-27 | Centre Nat Rech Scient | NOUVEAUX PYRROLO °2,3-a! CARBAZOLES ET LEUR UTILISATION COMME INHIBITEURS DES KINASES PIM |
| TWI496779B (zh) | 2008-08-19 | 2015-08-21 | Array Biopharma Inc | 作為ｐｉｍ激酶抑制劑之三唑吡啶化合物 |
| US8557809B2 (en) | 2008-08-19 | 2013-10-15 | Array Biopharma Inc. | Triazolopyridine compounds as PIM kinase inhibitors |
| RS53382B (sr) | 2008-08-20 | 2014-10-31 | Zoetis Llc | Jedinjenja pirol [2,3-d]pirimidina |
| BRPI0918496A2 (pt) | 2008-09-02 | 2019-09-24 | Novartis Ag | composto inibidor bicíclico de quinase, uso do mesmo, composição farmacêutica e método para inibir a atividade da quinase pim em uma célula |
| AU2009289319C1 (en) | 2008-09-02 | 2013-12-05 | Novartis Ag | Picolinamide derivatives as kinase inhibitors |
| MX2011002362A (es) | 2008-09-02 | 2011-04-04 | Novartis Ag | Inhibidores heterociclicos de cinasa pim. |
| CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| US20110183958A1 (en) | 2008-10-17 | 2011-07-28 | Merck Frosst Canada Ltd. | Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| JOP20190230A1 (ar) | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
| EP2210890A1 (en) | 2009-01-19 | 2010-07-28 | Almirall, S.A. | Oxadiazole derivatives as S1P1 receptor agonists |
| US8263601B2 (en) | 2009-02-27 | 2012-09-11 | Concert Pharmaceuticals, Inc. | Deuterium substituted xanthine derivatives |
| CA2762174C (en) | 2009-05-22 | 2018-02-20 | Incyte Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| TWI484962B (zh) | 2009-05-22 | 2015-05-21 | Incyte Corp | 作為ｊａｋ抑制劑之３－〔４－（７ｈ－吡咯并〔２，３－ｄ〕嘧啶－４－基）－１ｈ－吡唑－１－基〕辛烷或庚腈 |
| UA110324C2 (en) | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| TW201105674A (en) | 2009-07-08 | 2011-02-16 | Leo Pharma As | Novel JAK receptor and protein tyrosine kinase inhibitors and pharmaceutical use thereof |
| EP2470534A4 (en) | 2009-08-24 | 2013-02-27 | Merck Sharp & Dohme | JAK INHIBITION FOR BLOCKING TOXICITY ASSOCIATED WITH RNA INTERFERENCE |
| TW201111385A (en) | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| EP2475659B1 (en) | 2009-09-08 | 2015-10-28 | F.Hoffmann-La Roche Ag | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use |
| EP2305660A1 (en) | 2009-09-25 | 2011-04-06 | Almirall, S.A. | New thiadiazole derivatives |
| CA2777114C (en) | 2009-10-09 | 2018-10-23 | Incyte Corporation | Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| KR20120102601A (ko) | 2009-10-20 | 2012-09-18 | 셀좀 리미티드 | Ｊａｋ 저해제로서의 헤테로시클릴 피라졸로피리미딘 유사체 |
| US20110113416A1 (en) | 2009-11-09 | 2011-05-12 | Bank Of America Corporation | Network-Enhanced Control Of Software Updates Received Via Removable Computer-Readable Medium |
| EP2332917B1 (en) | 2009-11-11 | 2012-08-01 | Sygnis Bioscience GmbH & Co. KG | Compounds for PIM kinase inhibition and for treating malignancy |
| US20120294852A1 (en) | 2009-11-24 | 2012-11-22 | Smith Jeffrey T L | Antagonists of il-6 to raise albumin and/or lower crp |
| WO2011069141A2 (en) | 2009-12-04 | 2011-06-09 | Board Of Regents, The University Of Texas System | Interferon therapies in combination with blockade of stat3 activation |
| ES2461967T3 (es) | 2009-12-18 | 2014-05-21 | Pfizer Inc. | Compuestos de pirrolo[2,3-d]pirimidina |
| MX2012008049A (es) | 2010-01-12 | 2012-08-01 | Hoffmann La Roche | Compuestos heterociclicos triciclicos, composiciones y metodos de uso de los mismos,. |
| SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
| KR101836538B1 (ko) * | 2010-02-18 | 2018-03-08 | 인사이트 홀딩스 코포레이션 | 야누스 키나아제 억제제로서의 사이클로부탄 및 메틸사이클로부탄 유도체 |
| ME02386B (me) * | 2010-03-10 | 2016-09-20 | Incyte Holdings Corp | Derivati piperidin-4-il azetidina kao inhibitori jak1 |
| KR20130094710A (ko) | 2010-04-14 | 2013-08-26 | 어레이 바이오파마 인크. | Ｊａｋ 키나아제의 억제제로서 5,7-치환된-이미다조［1,2-ｃ］피리미딘 |
| EP2390252A1 (en) | 2010-05-19 | 2011-11-30 | Almirall, S.A. | New pyrazole derivatives |
| SG185567A1 (en) | 2010-05-21 | 2012-12-28 | Incyte Corp | Topical formulation for a jak inhibitor |
| WO2011156698A2 (en) | 2010-06-11 | 2011-12-15 | Abbott Laboratories | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS |
| US9351943B2 (en) | 2010-07-01 | 2016-05-31 | Matthew T. McLeay | Anti-fibroblastic fluorochemical emulsion therapies |
| WO2012045020A1 (en) | 2010-09-30 | 2012-04-05 | Portola Pharmaceuticals, Inc. | Combinations of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine |
| US9034884B2 (en) * | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
| US8933085B2 (en) * | 2010-11-19 | 2015-01-13 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
| WO2012071612A1 (en) | 2010-12-03 | 2012-06-07 | Ym Biosciences Australia Pty Ltd | Treatment of jak2-mediated conditions |
| PT2675451E (pt) * | 2011-02-18 | 2015-10-16 | Incyte Corp | Terapia de combinação com inibidores mtor/jak |
| CN102247368B (zh) | 2011-05-19 | 2013-05-29 | 安徽永生堂药业有限责任公司 | 一种复方阿伐斯汀缓释片及其制备方法 |
| CN102218042A (zh) | 2011-05-26 | 2011-10-19 | 青岛黄海制药有限责任公司 | 富马酸喹硫平组合物的缓释片剂及其制备方法 |
| BR112013032720A2 (pt) | 2011-06-20 | 2016-09-13 | Incyte Corp | "derivados de azetidinil fenil, piridil ou pirazinil carboxamida como inibidores de jak, composição e uso dos referidos derivados" |
| WO2013007765A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Fused tricyclic compounds for use as inhibitors of janus kinases |
| WO2013007768A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
| US9358229B2 (en) * | 2011-08-10 | 2016-06-07 | Novartis Pharma Ag | JAK PI3K/mTOR combination therapy |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| AR091079A1 (es) | 2012-05-18 | 2014-12-30 | Incyte Corp | Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak |
| US10155987B2 (en) | 2012-06-12 | 2018-12-18 | Dana-Farber Cancer Institute, Inc. | Methods of predicting resistance to JAK inhibitor therapy |
| EP3450434B1 (en) | 2012-06-15 | 2021-02-24 | CoNCERT Pharmaceuticals, Inc. | Deuterated derivatives of ruxolitinib |
| EA201590272A1 (ru) | 2012-07-27 | 2015-05-29 | Рациофарм Гмбх | Пероральные дозированные формы для модифицированного высвобождения, содержащие руксолитиниб |
| CN102772384A (zh) | 2012-08-07 | 2012-11-14 | 四川百利药业有限责任公司 | 一种盐酸米诺环素缓释片及其制备方法 |
| US9573958B2 (en) | 2012-08-31 | 2017-02-21 | Principia Biopharma, Inc. | Benzimidazole derivatives as ITK inhibitors |
| PE20151141A1 (es) | 2012-11-01 | 2015-08-06 | Incyte Corp | Derivados triciclicos fusionados de tiofeno como inhibidores de jak |
| TW202228704A (zh) | 2012-11-15 | 2022-08-01 | 美商英塞特控股公司 | 盧梭利替尼之緩釋性劑型 |
| PT3489239T (pt) | 2013-03-06 | 2021-12-17 | Incyte Holdings Corp | Processos e intermediários para a preparação de um inibidor de jak |
| KR102729910B1 (ko) | 2013-05-17 | 2024-11-15 | 인사이트 홀딩스 코포레이션 | Ｊａｋ 저해제로서 비피라졸 유도체 |
| MY203694A (en) | 2013-08-07 | 2024-07-14 | Incyte Holdings Corp | Sustained release dosage forms for a jak1 inhibitor |
| WO2015026818A1 (en) | 2013-08-20 | 2015-02-26 | Incyte Corporation | Survival benefit in patients with solid tumors with elevated c-reactive protein levels |
| KR20160136323A (ko) | 2014-02-28 | 2016-11-29 | 인사이트 코포레이션 | 골수형성이상증후군 치료용 jak1 억제제 |
| DK3129021T3 (da) | 2014-04-08 | 2020-11-09 | Incyte Corp | Behandling af b-celle-maligniteter ved en kombination af jak- og pi3k-inhibitorer |
| SG11201609016VA (en) | 2014-04-30 | 2016-11-29 | Incyte Corp | Processes of preparing a jak1 inhibitor and new forms thereto |
| EP3148545B1 (en) | 2014-05-28 | 2023-03-15 | Onco Tracker, Inc. | Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids |
| US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
| US10766900B2 (en) | 2017-12-29 | 2020-09-08 | Formosa Laboratories, Inc. | Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof |
| AU2020219797B2 (en) | 2019-02-06 | 2025-10-16 | Sun Pharmaceutical Industries, Inc. | Process for preparing enantiomerically enriched jak inhibitors |
-
2011
- 2011-03-09 ME MEP-2016-41A patent/ME02386B/me unknown
- 2011-03-09 KR KR1020187013055A patent/KR101911697B1/ko active Active
- 2011-03-09 CN CN201180023757.7A patent/CN102985417B/zh active Active
- 2011-03-09 MX MX2019005232A patent/MX380755B/es unknown
- 2011-03-09 RS RS20160205A patent/RS54823B1/sr unknown
- 2011-03-09 ES ES20158754T patent/ES2908412T3/es active Active
- 2011-03-09 HU HUE17211097A patent/HUE049914T2/hu unknown
- 2011-03-09 RS RS20180368A patent/RS57219B1/sr unknown
- 2011-03-09 JP JP2012557194A patent/JP5858484B2/ja active Active
- 2011-03-09 ES ES15195698.4T patent/ES2662588T3/es active Active
- 2011-03-09 MX MX2017006392A patent/MX354212B/es unknown
- 2011-03-09 LT LTEP17211097.5T patent/LT3354652T/lt unknown
- 2011-03-09 PE PE2012001467A patent/PE20130038A1/es active IP Right Grant
- 2011-03-09 DK DK11711709.3T patent/DK2545045T3/en active
- 2011-03-09 EP EP11711709.3A patent/EP2545045B1/en active Active
- 2011-03-09 DK DK15195698.4T patent/DK3050882T3/en active
- 2011-03-09 SI SI201130747A patent/SI2545045T1/sl unknown
- 2011-03-09 MY MYPI2012003994A patent/MY175156A/en unknown
- 2011-03-09 EP EP15195698.4A patent/EP3050882B1/en not_active Revoked
- 2011-03-09 WO PCT/US2011/027665 patent/WO2011112662A1/en not_active Ceased
- 2011-03-09 ES ES17211097T patent/ES2796377T3/es active Active
- 2011-03-09 TW TW107139196A patent/TWI694826B/zh active
- 2011-03-09 MX MX2012010344A patent/MX336932B/es active IP Right Grant
- 2011-03-09 EA EA201290894A patent/EA030376B1/ru unknown
- 2011-03-09 SM SM20180137T patent/SMT201800137T1/it unknown
- 2011-03-09 TW TW106118905A patent/TWI643857B/zh active
- 2011-03-09 EP EP24165623.0A patent/EP4400172A3/en active Pending
- 2011-03-09 ES ES21213769T patent/ES2982015T3/es active Active
- 2011-03-09 LT LTEP15195698.4T patent/LT3050882T/lt unknown
- 2011-03-09 EP EP20158754.0A patent/EP3715347B1/en active Active
- 2011-03-09 TW TW100107955A patent/TWI531572B/zh active
- 2011-03-09 SG SG2012064457A patent/SG183551A1/en unknown
- 2011-03-09 MX MX2018002077A patent/MX364636B/es unknown
- 2011-03-09 KR KR1020217023315A patent/KR102354472B1/ko active Active
- 2011-03-09 KR KR1020207030868A patent/KR102283091B1/ko active Active
- 2011-03-09 KR KR1020207008092A patent/KR102172742B1/ko active Active
- 2011-03-09 AR ARP110100737A patent/AR081315A1/es active IP Right Grant
- 2011-03-09 HU HUE11711709A patent/HUE028723T2/en unknown
- 2011-03-09 TW TW109116080A patent/TWI766281B/zh active
- 2011-03-09 NO NO15195698A patent/NO3050882T3/no unknown
- 2011-03-09 US US13/043,986 patent/US8765734B2/en active Active
- 2011-03-09 RS RS20200725A patent/RS60680B1/sr unknown
- 2011-03-09 BR BR112012022513A patent/BR112012022513A2/pt not_active Application Discontinuation
- 2011-03-09 PH PH12015502575A patent/PH12015502575A1/en unknown
- 2011-03-09 PT PT151956984T patent/PT3050882T/pt unknown
- 2011-03-09 HR HRP20160326TT patent/HRP20160326T1/hr unknown
- 2011-03-09 PL PL15195698T patent/PL3050882T3/pl unknown
- 2011-03-09 KR KR1020127026216A patent/KR101857680B1/ko active Active
- 2011-03-09 PL PL17211097T patent/PL3354652T3/pl unknown
- 2011-03-09 EP EP21213769.9A patent/EP4036088B1/en active Active
- 2011-03-09 NZ NZ602313A patent/NZ602313A/en unknown
- 2011-03-09 SM SM20200373T patent/SMT202000373T1/it unknown
- 2011-03-09 KR KR1020187030015A patent/KR20180117206A/ko not_active Ceased
- 2011-03-09 TW TW111114548A patent/TWI850648B/zh active
- 2011-03-09 AU AU2011224484A patent/AU2011224484A1/en not_active Abandoned
- 2011-03-09 PT PT172110975T patent/PT3354652T/pt unknown
- 2011-03-09 SI SI201131432T patent/SI3050882T1/en unknown
- 2011-03-09 MX MX2016001708A patent/MX347851B/es unknown
- 2011-03-09 DK DK17211097.5T patent/DK3354652T3/da active
- 2011-03-09 CA CA2792508A patent/CA2792508C/en active Active
- 2011-03-09 ES ES11711709T patent/ES2569539T3/es active Active
- 2011-03-09 PL PL11711709T patent/PL2545045T3/pl unknown
- 2011-03-09 HU HUE15195698A patent/HUE037077T2/hu unknown
- 2011-03-09 SI SI201131892T patent/SI3354652T1/sl unknown
- 2011-03-09 EP EP17211097.5A patent/EP3354652B1/en active Active
- 2011-03-09 TW TW105101410A patent/TWI592413B/zh active
- 2011-03-09 PH PH1/2012/501768A patent/PH12012501768A1/en unknown
- 2011-03-09 KR KR1020227001841A patent/KR20220015492A/ko not_active Withdrawn
-
2012
- 2012-09-06 IL IL221823A patent/IL221823A/en active IP Right Grant
- 2012-09-10 CL CL2012002501A patent/CL2012002501A1/es unknown
- 2012-09-14 CO CO12158921A patent/CO6602158A2/es unknown
- 2012-10-03 ZA ZA2012/07420A patent/ZA201207420B/en unknown
- 2012-10-03 EC ECSP12012218 patent/ECSP12012218A/es unknown
- 2012-10-08 CR CR20120510A patent/CR20120510A/es unknown
- 2012-11-16 MY MYPI2016000078A patent/MY192255A/en unknown
-
2014
- 2014-05-28 US US14/289,121 patent/US9464088B2/en active Active
-
2015
- 2015-12-10 JP JP2015241393A patent/JP6158282B2/ja active Active
-
2016
- 2016-03-24 SM SM201600085T patent/SMT201600085B/it unknown
- 2016-10-07 US US15/288,641 patent/US9999619B2/en active Active
-
2017
- 2017-06-07 JP JP2017112574A patent/JP6318291B2/ja active Active
-
2018
- 2018-03-09 ME MEP-2018-86A patent/ME03002B/me unknown
- 2018-04-02 JP JP2018070780A patent/JP2018118992A/ja active Pending
- 2018-04-05 HR HRP20180552TT patent/HRP20180552T1/hr unknown
- 2018-04-16 CY CY20181100397T patent/CY1120154T1/el unknown
- 2018-06-01 US US15/995,323 patent/US10695337B2/en active Active
-
2020
- 2020-04-09 JP JP2020070257A patent/JP2020114868A/ja active Pending
- 2020-05-19 US US16/878,281 patent/US11285140B2/en active Active
- 2020-07-10 HR HRP20201086TT patent/HRP20201086T1/hr unknown
- 2020-07-22 CY CY20201100671T patent/CY1123175T1/el unknown
-
2022
- 2022-02-17 US US17/674,237 patent/US20230043959A1/en active Pending
-
2023
- 2023-05-17 JP JP2023081459A patent/JP7592784B2/ja active Active
-
2024
- 2024-11-20 JP JP2024201971A patent/JP2025019114A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR081315A1 (es) | Derivados heterociclicos de piperidin y pirimidin -4-il-azetidina, una forma cristalina de la sal del acido acetonitriladipico de un derivado pirimidinico, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades relacionadas con la inhibicion de jak-1, t | |
| AR083933A1 (es) | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak | |
| DOP2012000310A (es) | Morfolinopirimidinas y su uso en terapia | |
| ES2616477T3 (es) | Heterociclaminas como inhibidores de pi3k | |
| AR098549A1 (es) | Derivados de amino pirimidina | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
| AR087591A1 (es) | Derivados de ciclohexil azetidina como inhibidores de jak | |
| PE20161475A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
| ME02382B (me) | 2-(2,4,5-supstituisani-anilino) piramidisnki derivati kao egfr modulatori korisni za tretman raka | |
| AR082102A1 (es) | Derivados de acido (2-ariloxiacetilamino)fenilpropionico, procedimientos para su preparacion y uso de los mismos como medicamentos | |
| AR078944A1 (es) | Inhibidores de n1-pirazoloespirocetona acetil-coa carboxilasa | |
| AR067413A1 (es) | Compuestos heterociclicos que contienen ciclopenta[d]pirimidina inhibidores de proteinquinasas akt, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de las mismas para el tratamiento de enfermedades hiperproliferativas, tales como cancer | |
| AR083813A1 (es) | Derivados de pirazol aminopirimidina como moduladores de lrrk2 | |
| AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| BR112014001468A2 (pt) | compostos de tetra-hidropirido-piridina e tetra-hidropirido-pirimidina e uso dos mesmos como modulares do receptor c5a | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR077434A1 (es) | Compuestos para la reduccion de produccion de beta - amiloide | |
| AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| RU2014129742A (ru) | Производные бензолсульфонамида в качестве модуляторов rorc | |
| PE20130602A1 (es) | Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a | |
| AR082101A1 (es) | Acidos de hidroxifenilhexinoico ariloxialquileno-sustituido, procedimiento para su preparacion y su uso como medicamento | |
| AR085489A1 (es) | Derivados de triazolopiridinas, composiciones farmaceuticas que los contienen, proceso para prepararlos, intermediarios de dicho proceso y uso de los mismos para el tratamiento de enfermedades autoinmunes e inflamatorias | |
| AR086100A1 (es) | Compuestos de cromenona y composiciones farmaceuticas que los contienen | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR094975A1 (es) | Dihidropirimidinonas bicíclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrofílica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |